Home > Research > Publications & Outputs > Cost-Effectiveness of Optimizing Use of Statins...
View graph of relations

Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry. / Ademi, Zanfina ; Reid, Chris; Hollingsworth, Bruce; Stoelwinder, Johannes; Steg, Phillipe Gabriel; Bhatt, Deepak L.; Vale, Margarite; Liew, Danny.

In: Clinical Therapeutics, Vol. 33, No. 10, 10.2011, p. 1456-1465.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Ademi, Z, Reid, C, Hollingsworth, B, Stoelwinder, J, Steg, PG, Bhatt, DL, Vale, M & Liew, D 2011, 'Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry', Clinical Therapeutics, vol. 33, no. 10, pp. 1456-1465. https://doi.org/10.1016/j.clinthera.2011.08.004

APA

Ademi, Z., Reid, C., Hollingsworth, B., Stoelwinder, J., Steg, P. G., Bhatt, D. L., Vale, M., & Liew, D. (2011). Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry. Clinical Therapeutics, 33(10), 1456-1465. https://doi.org/10.1016/j.clinthera.2011.08.004

Vancouver

Author

Ademi, Zanfina ; Reid, Chris ; Hollingsworth, Bruce ; Stoelwinder, Johannes ; Steg, Phillipe Gabriel ; Bhatt, Deepak L. ; Vale, Margarite ; Liew, Danny. / Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry. In: Clinical Therapeutics. 2011 ; Vol. 33, No. 10. pp. 1456-1465.

Bibtex

@article{94e7df4282ee47acb93de14f6438c927,
title = "Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry",
abstract = "ObjectiveThe goal of this study was to estimate the cost-effectiveness of closing the statin “treatment gap” in the secondary prevention of coronary artery disease (CAD) in Australia.MethodsA decision analysis Markov model was developed with yearly cycles and the health states of alive or dead. Using data from the Australian Reduction of Atherothrombosis for Continued Health Registry, the model compared current statin coverage (82%) in the secondary prevention of CAD (the current group) with a hypothetical situation of 100% coverage (the improved group). The 18% gap was filled with use of generic statins. Data from a recent meta-analysis were used to estimate the benefits of statin use in terms of reducing recurrent cardiovascular events and death. Government reimbursement data from 2011 were used to calculate direct health care costs. The cost of the intervention to improve statin coverage was assumed to be $250 per person. Years of life lived and costs were discounted at 5% annually. All values are given in Australian dollars.ResultsAmong the 2058 subjects in the current group, the model estimated that there would be 106 nonfatal myocardial infractions, 68 nonfatal strokes, and 275 deaths over 5 years. In the improved group, all of whom took statins, the corresponding numbers were 101, 65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively. Over the 5 years, there would be 0.018 life-years gained (discounted) at a net cost of $546 (discounted) per person. These equated to an incremental cost-effectiveness ratio of $29,717 per life-year gained.ConclusionThe results suggest that for patients with CAD, maximizing coverage with statins, in line with evidence-based recommendations, represents a cost-effective means of secondary prevention.",
keywords = "coronary artery disease, cost-effectiveness analysis , registries , statins",
author = "Zanfina Ademi and Chris Reid and Bruce Hollingsworth and Johannes Stoelwinder and Steg, {Phillipe Gabriel} and Bhatt, {Deepak L.} and Margarite Vale and Danny Liew",
year = "2011",
month = oct,
doi = "10.1016/j.clinthera.2011.08.004",
language = "English",
volume = "33",
pages = "1456--1465",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "10",

}

RIS

TY - JOUR

T1 - Cost-Effectiveness of Optimizing Use of Statins in Australia: Using Outpatient Data From the REACH Registry

AU - Ademi, Zanfina

AU - Reid, Chris

AU - Hollingsworth, Bruce

AU - Stoelwinder, Johannes

AU - Steg, Phillipe Gabriel

AU - Bhatt, Deepak L.

AU - Vale, Margarite

AU - Liew, Danny

PY - 2011/10

Y1 - 2011/10

N2 - ObjectiveThe goal of this study was to estimate the cost-effectiveness of closing the statin “treatment gap” in the secondary prevention of coronary artery disease (CAD) in Australia.MethodsA decision analysis Markov model was developed with yearly cycles and the health states of alive or dead. Using data from the Australian Reduction of Atherothrombosis for Continued Health Registry, the model compared current statin coverage (82%) in the secondary prevention of CAD (the current group) with a hypothetical situation of 100% coverage (the improved group). The 18% gap was filled with use of generic statins. Data from a recent meta-analysis were used to estimate the benefits of statin use in terms of reducing recurrent cardiovascular events and death. Government reimbursement data from 2011 were used to calculate direct health care costs. The cost of the intervention to improve statin coverage was assumed to be $250 per person. Years of life lived and costs were discounted at 5% annually. All values are given in Australian dollars.ResultsAmong the 2058 subjects in the current group, the model estimated that there would be 106 nonfatal myocardial infractions, 68 nonfatal strokes, and 275 deaths over 5 years. In the improved group, all of whom took statins, the corresponding numbers were 101, 65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively. Over the 5 years, there would be 0.018 life-years gained (discounted) at a net cost of $546 (discounted) per person. These equated to an incremental cost-effectiveness ratio of $29,717 per life-year gained.ConclusionThe results suggest that for patients with CAD, maximizing coverage with statins, in line with evidence-based recommendations, represents a cost-effective means of secondary prevention.

AB - ObjectiveThe goal of this study was to estimate the cost-effectiveness of closing the statin “treatment gap” in the secondary prevention of coronary artery disease (CAD) in Australia.MethodsA decision analysis Markov model was developed with yearly cycles and the health states of alive or dead. Using data from the Australian Reduction of Atherothrombosis for Continued Health Registry, the model compared current statin coverage (82%) in the secondary prevention of CAD (the current group) with a hypothetical situation of 100% coverage (the improved group). The 18% gap was filled with use of generic statins. Data from a recent meta-analysis were used to estimate the benefits of statin use in terms of reducing recurrent cardiovascular events and death. Government reimbursement data from 2011 were used to calculate direct health care costs. The cost of the intervention to improve statin coverage was assumed to be $250 per person. Years of life lived and costs were discounted at 5% annually. All values are given in Australian dollars.ResultsAmong the 2058 subjects in the current group, the model estimated that there would be 106 nonfatal myocardial infractions, 68 nonfatal strokes, and 275 deaths over 5 years. In the improved group, all of whom took statins, the corresponding numbers were 101, 65, and 259, equating to numbers needed to treat of 426, 639, and 127, respectively. Over the 5 years, there would be 0.018 life-years gained (discounted) at a net cost of $546 (discounted) per person. These equated to an incremental cost-effectiveness ratio of $29,717 per life-year gained.ConclusionThe results suggest that for patients with CAD, maximizing coverage with statins, in line with evidence-based recommendations, represents a cost-effective means of secondary prevention.

KW - coronary artery disease

KW - cost-effectiveness analysis

KW - registries

KW - statins

U2 - 10.1016/j.clinthera.2011.08.004

DO - 10.1016/j.clinthera.2011.08.004

M3 - Journal article

VL - 33

SP - 1456

EP - 1465

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 10

ER -